Cingulate

Cingulate Short-term Debt

The Short-Term Debt of Cingulate (CING) as of Nov 11, 2026 is 6.53 M USD. In the previous year, Short-Term Debt was 2.66 M USD — a change of 145.47% (higher).

Short-term Debt

6.53 MUSD

YoY

145.47%

Last updated:

Short-Term Debt of Cingulate is 2025 6.53 M USD. Short-Term Debt of Cingulate was 2024 2.66 M USD. It decreases by 145.47% higher compared to the previous year.

The Cingulate Short-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Short-term Debt
Date
Short-term Debt
Jan 1, 2019
375,818.00 USD
Jan 1, 2020
936,594.00 USD
Jan 1, 2021
310,691.00 USD
Jan 1, 2022
5.36 M USD
Jan 1, 2023
3.38 M USD
Jan 1, 2024
2.66 M USD
Jan 1, 2025
6.53 M USD
The Cingulate Short-term Debt history
YEARShort-term DebtYoY
6.53 MUSD+145.47%
2.66 MUSD-21.12%
3.38 MUSD-36.98%
5.36 MUSD+1,623.84%
310,691.00USD-66.83%
936,594.00USD+149.21%
375,818.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cingulate Stock analysis

What does Cingulate do? Cingulate Inc is a US-based biopharmaceutical company headquartered in Kansas City, Kansas, that focuses on the development, manufacturing, and commercialization of pharmaceutical products. The firm utilizes its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles designed to improve the lives of patients suffering from commonly diagnosed conditions. The company specifically targets the treatment of attention deficit/hyperactivity disorder (ADHD) through its innovative approach to drug delivery. The firm is currently developing two lead product candidates, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). These drug candidates both contain three releases of an active pharmaceutical ingredient combined into one small tablet dosage form. By employing this technology, Cingulate Inc aims to provide effective treatment options for ADHD across three core patient segments: children aged 6-12, adolescents aged 13-17, and adults aged 18 and older. Cingulate is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cingulate stock

Short-Term Debt of Cingulate is 6.53 M USD in 2025.

Short-Term Debt of Cingulate changed from 2.66 M USD to 6.53 M USD, representing a 145.47% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Short-Term Debt Cingulate since 2006 – with annual values, charts, and detailed analysis.

Short-term debt represents borrowings due within one year. High short-term debt relative to cash can signal liquidity risk.

Short-Term Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Short-Term Debt's Cingulate historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Cingulate

All Key Metrics — Cingulate